Request Demo
Recent blog posts
Latest Hotspot
8 min read
CTR20260926 Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin) Diarrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
CTR20260926 clinical trial report covering Recombinant acylated glucagon-like peptide 2 analogue(Chongqing Paijin), Phase 2, endpoints, sponsor, geography,
Latest Hotspot
8 min read
NCT07472725 SHR-3167 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07472725 clinical trial report covering SHR-3167, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07472933 Tislelizumab Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07472933 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07473700 TX-000045 Familial Hypersensitivity Pneumonitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07473700 clinical trial report covering TX-000045, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07475286 Mitomycin Peritoneal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07475286 clinical trial report covering Mitomycin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477301 Risperidone Cognitive Dysfunction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477301 clinical trial report covering Risperidone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477288 Gamma-Aminobutyric Acid Skin aging Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477288 clinical trial report covering Gamma-Aminobutyric Acid, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ISRCTN16472226 Sutacimig Genetic Diseases, Inborn Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ISRCTN16472226 clinical trial report covering Sutacimig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07476794 Temozolomide Glioblastoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07476794 clinical trial report covering Temozolomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07477431 Levetiracetam Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07477431 clinical trial report covering Levetiracetam, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120552 Lenvatinib mesylate Locally Advanced Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120552 clinical trial report covering Lenvatinib mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031250820 Givastomig Liver metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
JPRN-jRCT2031250820 clinical trial report covering Givastomig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.